Clinical Trials Directory

Trials / Completed

CompletedNCT05216822

Anti-Secretory Drug in Treatment of Acute Watery Diarrhea

Role of Anti-Secretory Drug in Treatment of Children With Acute Watery Diarrhea

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
6 Months – 5 Years
Healthy volunteers
Not accepted

Summary

In conclusion, racecadotril is an anti-secretory drug that exerts its antidiarrheal effect by inhibiting intestinal enkephalinase. It is effective in reducing the volume and frequency of stool output. racecadotril is well tolerated and safe by providing symptomatic relief and reducing the severity of diarrhea as an adjuvant therapy during the acute attack of gastroenteritis. It is recommended that the new generations of already discovered drugs for control of secretory diarrhea should be studied to discover the ones with fewer side effects to other systems in the body.

Detailed description

Background: Previous studies have shown that racecadotril is a safe and effective drug in treating children with acute diarrhea. Study Aim: to evaluate the effect of racecadotril as an adjunct to oral rehydration solution in the treatment of acute watery diarrhea among children under 5 years of age. Subjects and methods: This RCT trial included 50 children with acute watery diarrhea for 5 days or less with a frequency of three or more diarrheic stools in the past 24 hours before admission to the hospital, with no/mild to moderate dehydration.

Conditions

Interventions

TypeNameDescription
DRUGRacecadotrilracecadotril (dose of 1.5 mg/kg/day, an oral single daily dose for three days

Timeline

Start date
2018-06-01
Primary completion
2018-07-31
Completion
2018-08-31
First posted
2022-02-01
Last updated
2022-02-01

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05216822. Inclusion in this directory is not an endorsement.